Literature DB >> 33936598

Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.

Toshiki Terao1,2, Junichiro Yuda1, Nobuhiko Yamauchi1, Yong-Mei Guo1, Kaoru Shimada3, Masato Sugano4, Genichiro Ishii4, Yosuke Minami1.   

Abstract

Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL. Copyright: © Terao et al.

Entities:  

Keywords:  CD30; brentuximab vedotin; gray zone lymphoma; refractory; relapsed

Year:  2021        PMID： 33936598      PMCID： PMC8082227          DOI： 10.3892/mco.2021.2287

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN： 2049-9450


  13 in total

1.  Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Authors:  Andrew M Evens; Jennifer A Kanakry; Laurie H Sehn; Athena Kritharis; Tatyana Feldman; Aimee Kroll; Randy D Gascoyne; Jeremy S Abramson; Adam M Petrich; Francisco J Hernandez-Ilizaliturri; Zeina Al-Mansour; Camille Adeimy; Jessica Hemminger; Nancy L Bartlett; Anthony Mato; Paolo F Caimi; Ranjana H Advani; Andreas K Klein; Chadi Nabhan; Sonali M Smith; Jesus C Fabregas; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum
Journal:  Am J Hematol       Date:  2015-09       Impact factor: 10.047

2.  Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

Authors:  Craig H Moskowitz; Jan Walewski; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Simonetta Viviani; Veronika Bachanova; Anna Sureda; Teresa McClendon; Connie Lee; Julie Lisano; John Sweetenham
Journal:  Blood       Date:  2018-09-28       Impact factor: 22.113

Review 3.  How I manage patients with grey zone lymphoma.

Authors:  Athena Kritharis; Monika Pilichowska; Andrew M Evens
Journal:  Br J Haematol       Date:  2016-06-15       Impact factor: 6.998

4.  Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.

Authors:  Jamilla Li; Joycelyn Sim; Anskar Y H Leung; Yok-Lam Kwong
Journal:  Ann Hematol       Date:  2017-12-02       Impact factor: 3.673

5.  Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.

Authors:  Kazutoshi Ebisawa; Yosuke Masamoto; Junji Koya; Arika Shimura; Aya Shinozaki-Ushiku; Kazuhiro Toyama; Kumi Nakazaki; Mineo Kurokawa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-08-30

6.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

8.  Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.

Authors:  Alexandra Traverse-Glehen; Stefania Pittaluga; Philippe Gaulard; Lynn Sorbara; Miguel A Alonso; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

9.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  1 in total

1.  Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Authors:  Nobumasa Hojo; Makoto Nagasaki; Yasuha Mihara
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.